New York Approves Foundation Medicine to Offer Cancer Sequencing Tests | GenomeWeb

NEW YORK (GenomeWeb) – The New York State Department of Health has given its approval to Foundation Medicine to perform its FoundationOne and FoundationOne Heme tests on residents of New York State.

FoundationOne is a targeted genomic sequencing test for solid tumors that profiles the coding regions of 236 cancer-related genes, as well as 47 introns from 19 other genes for alterations associated with existing and experimental molecularly targeted therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.